Favipiravir in the Battle with Respiratory Viruses.
Mini Rev Med Chem
; 22(17): 2224-2236, 2022.
Article
in English
| MEDLINE | ID: covidwho-1700911
ABSTRACT
Among antiviral drugs, the vast majority targets only one or two related viruses. The conventional model, one virus - one drug, significantly limits therapeutic options. Therefore, in the strategy of controlling viral infections, there is a necessity to develop compounds with pleiotropic effects. Favipiravir (FPV) emerged as a strong candidate to become such a drug. The aim of the study is to present up-to-date information on the role of favipiravir in the treatment of viral respiratory infections. The anti-influenza activity of favipiravir has been confirmed in cell culture experiments, animal models, and clinical trials. Thoroughly different - from the previously registered drugs - mechanism of action suggests that FVP can be used as a countermeasure for the novel or re-emerging influenza virus infections. In recent months, favipiravir has been broadly investigated due to its potential efficacy in the treatment of COVID-19. Based on preclinical and clinical studies and a recently published meta-analysis it seems that favipiravir may be a promising antiviral drug in the treatment of patients with COVID-19. FPV is also effective against other RNA respiratory viruses and may be a candidate for the treatment of serious infections caused by human rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza viruses and hantavirus pulmonary syndrome.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
RNA Viruses
/
Viruses
/
Virus Diseases
/
COVID-19
Type of study:
Prognostic study
/
Reviews
Limits:
Animals
/
Humans
Language:
English
Journal:
Mini Rev Med Chem
Journal subject:
Chemistry
Year:
2022
Document Type:
Article
Affiliation country:
1389557522666220218122744
Similar
MEDLINE
...
LILACS
LIS